 HYDERABAD, India PRINCETON, N.J.--BUSINESS WIRE--Dr. Reddys Laboratories Ltd. BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY along with its subsidiaries together referred to as Dr. Reddys today announced the launch of Fluphenazine Hydrochloride Tablets, USP, a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg, and 10 mg, approved by the U.S. Food and Drug Administration USFDA. The Prolixin brand and generic had U.S. sales of approximately 134 mi 